AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.842312746386334
- age_years
- 47
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.637
- INTERFERON_GAMMA_RESPONSE+0.621
- ANGIOGENESIS+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.597
- ALLOGRAFT_REJECTION+0.594
- IL6_JAK_STAT3_SIGNALING+0.587
- INFLAMMATORY_RESPONSE+0.560
- E2F_TARGETS+0.509
- TNFA_SIGNALING_VIA_NFKB+0.498
- MYC_TARGETS_V1+0.493
Top 10 suppressed
- KRAS_SIGNALING_DN-0.165
- MITOTIC_SPINDLE-0.111
- SPERMATOGENESIS-0.100
- HEDGEHOG_SIGNALING-0.028
- WNT_BETA_CATENIN_SIGNALING-0.014
- BILE_ACID_METABOLISM+0.000
- UV_RESPONSE_DN+0.005
- HEME_METABOLISM+0.014
- ESTROGEN_RESPONSE_EARLY+0.019
- APICAL_SURFACE+0.047
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.978 |
| 2 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.967 |
| 3 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.966 |
| 4 | 788A8487-6A02-4BF5-8E84-16BE5D92BF0F | — | — | 0.963 |
| 5 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.963 |
| 6 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.962 |
| 7 | 3D3C3AAA-2C7A-43C6-8137-73A6E0896FAC | — | — | 0.961 |
| 8 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.959 |
| 9 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.958 |
| 10 | 3027792F-79B6-4729-9452-C4A72A7C4686 | — | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.637 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.621 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.597 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.594 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.587 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.509 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.498 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.493 | Inavolisib | — uncovered |
| COMPLEMENT | 0.491 | Inavolisib | — uncovered |
| APOPTOSIS | 0.458 | Idelalisib | — uncovered |
| COAGULATION | 0.457 | Binimetinib | — uncovered |
| HYPOXIA | 0.442 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.435 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.407 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.391 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.379 | Inavolisib | — uncovered |